SLPI抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P01814(SLPI Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

Secretory Leukocyte Protease Inhibitor (SLPI) is a small, cationic protein primarily produced by mucosal epithelial cells and immune cells. It plays a critical role in regulating inflammation and protecting tissues from protease-mediated damage by inhibiting enzymes like neutrophil elastase, cathepsin G, and trypsin. SLPI also exhibits antimicrobial, anti-inflammatory, and immunomodulatory properties, contributing to wound healing and maintaining mucosal barrier integrity. Its involvement in immune responses, particularly at mucosal surfaces (e.g., respiratory, oral, and reproductive tracts), has linked it to conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and HIV infection.

SLPI antibodies are tools used to detect and quantify SLPI expression in research and clinical settings. They enable studies on SLPI's dual role in health and disease—balancing tissue protection with potential contributions to pathological processes like cancer progression or viral persistence. Monoclonal and polyclonal antibodies against SLPI are utilized in techniques like ELISA, Western blot, and immunohistochemistry to explore its spatial distribution, regulation, and interactions with pathogens or host cells. Recent research focuses on SLPI's potential as a therapeutic target or biomarker in inflammatory diseases, autoimmune disorders, and infections, driving demand for specific, high-affinity antibodies to unravel its complex biological functions.